Summary | |
---|---|
Symbol | ICAM2 |
Name | intercellular adhesion molecule 2 |
Aliases | CD102; ICAM-2; CD antigen CD102 |
Chromosomal Location | 17q23.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Membrane Single-pass type I membrane protein Cell projection, microvillus Note=Co-localizes with RDX, EZR and MSN in microvilli. |
Domain |
PF03921 Intercellular adhesion molecule (ICAM) |
Function |
ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2). ICAM2 may play a role in lymphocyte recirculation by blocking LFA-1-dependent cell adhesion. It mediates adhesive interactions important for antigen-specific immune response, NK-cell mediated clearance, lymphocyte recirculation, and other cellular interactions important for immune response and surveillance. |
Biological Process |
GO:0002218 activation of innate immune response GO:0002220 innate immune response activating cell surface receptor signaling pathway GO:0002223 stimulatory C-type lectin receptor signaling pathway GO:0002429 immune response-activating cell surface receptor signaling pathway GO:0002757 immune response-activating signal transduction GO:0002758 innate immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0002768 immune response-regulating cell surface receptor signaling pathway GO:0030198 extracellular matrix organization GO:0031349 positive regulation of defense response GO:0043062 extracellular structure organization GO:0045088 regulation of innate immune response GO:0045089 positive regulation of innate immune response |
Molecular Function |
GO:0005178 integrin binding GO:0050839 cell adhesion molecule binding |
Cellular Component |
GO:0001931 uropod GO:0031254 cell trailing edge |
KEGG |
hsa04514 Cell adhesion molecules (CAMs) hsa04650 Natural killer cell mediated cytotoxicity |
Reactome |
R-HSA-1280218: Adaptive Immune System R-HSA-5621481: C-type lectin receptors (CLRs) R-HSA-5621575: CD209 (DC-SIGN) signaling R-HSA-1474244: Extracellular matrix organization R-HSA-168256: Immune System R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell R-HSA-168249: Innate Immune System R-HSA-216083: Integrin cell surface interactions |
Summary | |
---|---|
Symbol | ICAM2 |
Name | intercellular adhesion molecule 2 |
Aliases | CD102; ICAM-2; CD antigen CD102 |
Chromosomal Location | 17q23.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between ICAM2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between ICAM2 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | ICAM2 |
Name | intercellular adhesion molecule 2 |
Aliases | CD102; ICAM-2; CD antigen CD102 |
Chromosomal Location | 17q23.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of ICAM2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | ICAM2 |
Name | intercellular adhesion molecule 2 |
Aliases | CD102; ICAM-2; CD antigen CD102 |
Chromosomal Location | 17q23.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of ICAM2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of ICAM2 in various data sets.
|
Summary | |
---|---|
Symbol | ICAM2 |
Name | intercellular adhesion molecule 2 |
Aliases | CD102; ICAM-2; CD antigen CD102 |
Chromosomal Location | 17q23.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ICAM2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | ICAM2 |
Name | intercellular adhesion molecule 2 |
Aliases | CD102; ICAM-2; CD antigen CD102 |
Chromosomal Location | 17q23.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ICAM2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ICAM2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | ICAM2 |
Name | intercellular adhesion molecule 2 |
Aliases | CD102; ICAM-2; CD antigen CD102 |
Chromosomal Location | 17q23.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ICAM2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | ICAM2 |
Name | intercellular adhesion molecule 2 |
Aliases | CD102; ICAM-2; CD antigen CD102 |
Chromosomal Location | 17q23.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of ICAM2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | ICAM2 |
Name | intercellular adhesion molecule 2 |
Aliases | CD102; ICAM-2; CD antigen CD102 |
Chromosomal Location | 17q23.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between ICAM2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |